ATL/TV1102, a new anti-sense drug, significantly reduced MRI activity in patients with relapsing-remitting multiple sclerosis. Anti-sense drugs block disease-causing proteins from being made based on information in the genetic code. ATL/TV1102 may prevent white blood cells from entering sites of inflammation in the brain and spinal cord.
A randomized, double-blind, placebo-controlled Phase IIa study showed [...]

A Phase II/III study of Rituxan® (rituximab) for primary-progressive multiple sclerosis (PPMS) did not slow the likelihood of disease progression during the 96-week treatment period. A total of 439 patients from approximately 60 sites in the U.S. and Canada were randomized 2:1 to receive either four treatment courses of Rituxan six months apart or placebo. [...]